Biogen (BIIB)
(Delayed Data from NSDQ)
$224.94 USD
+4.87 (2.21%)
Updated May 31, 2024 04:00 PM ET
After-Market: $224.85 -0.09 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 461 - 480 ( 803 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Neurology Prescription Sales Tracker - Week Ending 5/8/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Remaining Focused on Bigger Picture, Aducanumab BLA Filing Expected 3Q20; Reit Buy and $335 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Aducanumab Pushing Out to FY21; Remain Cautious on Near-Term Setup
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
1Q20 First Take: BIIB Beats as Aducanumab Filing Progresses
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Neurology Prescription Sales Tracker -- Week Ending 4/10/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Neurology Prescription Sales Tracker -- Week Ending 4/03/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - Neurology Prescription Sales Tracker -- Week Ending 3/27/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department